



Syndros® (dronabinol) – Schedule change

- On May 25, 2017, the [FDA approved](#) changes to the scheduling for [Syndros \(dronabinol\)](#), from CX to CII, as per the [Federal register notice](#) dated March 23, 2017.
- Syndros is approved in adults for the treatment of anorexia associated with weight loss in patients with acquired immune deficiency syndrome and nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2017 Optum, Inc. All rights reserved.